Table 3. Univariate and multivariable analysis of the PFS of patients with max BTS ≥50 mm (n=90).
| Variables | Univariate analysis | Multivariable analysis1 | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | ||
| ICI-chemo vs. ICI-mono | 0.59 | 0.36–0.96 | 0.032 | 0.26 | 0.11–0.64 | 0.004 | |
| Number of organs involved (<3 vs. ≥3) | 0.62 | 0.38–1.03 | 0.066 | 0.74 | 0.43–1.28 | 0.282 | |
| PD-L1 TPS (≥50% vs. other) | 0.95 | 0.58–1.56 | 0.850 | 0.28 | 0.11–0.66 | 0.004 | |
| LIPI score (good vs. other) | 0.58 | 0.34–1.00 | 0.050 | 0.61 | 0.35–1.07 | 0.086 | |
| ECOG-PS (<2 vs. ≥2) | 0.58 | 0.34–1.00 | 0.051 | 0.71 | 0.38–1.35 | 0.300 | |
| Histological types (non-squamous vs. squamous) | 0.97 | 0.57–1.67 | 0.910 | NA | NA | NA | |
| Sex (male vs. female) | 0.76 | 0.42–1.38 | 0.372 | NA | NA | NA | |
| Age (<75 vs. ≥75) | 0.82 | 0.48–1.41 | 0.477 | NA | NA | NA | |
| Smoking status (Brinkman index <400 vs. ≥400) | 0.75 | 0.42–1.36 | 0.349 | NA | NA | NA | |
1, type of ICI treatment, PD-L1 TPS, variables with P<0.20 in the univariate analysis were included. PFS, progression-free survival; BTS, baseline tumor size; max BTS, maximum BTS; ICI, immune checkpoint inhibitor; ICI-mono, ICI monotherapy; ICI-chemo, ICI in combination with chemotherapy; PD-L1, programmed death ligand-1; TPS, tumor proportion score; LIPI, lung immune prognostic index; ECOG-PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; CI, confidence interval; NA, not available.